Bedrijfsoverzicht
CapsoVision, Inc. is a specialized medical technology firm dedicated to the manufacture and marketing of endoscopic video imaging devices, with a specific focus on internal visualization of the gastrointestinal system. The company operates within the Healthcare sector and the Medical Devices industry, positioning itself as a provider of advanced diagnostic solutions for visualizing the small bowel mucosa in both adult and pediatric populations. In terms of scale, the company maintains a market capitalization of $311.49M, generates annual revenue of $13.55M, and employs a workforce of 99 individuals. These valuation figures indicate that the market assigns a significant premium to the company's intellectual property and proprietary technology, suggesting that investors value the potential of its specialized imaging solutions far beyond the current revenue generated by existing product lines. The relatively small employee base of 99 suggests a highly specialized, perhaps asset-light operational model common in medical device development, where the primary value driver lies in the R&D and regulatory approval of the CapsoCam Plus system rather than in mass manufacturing scale.
Financiële gezondheid
The company reported a revenue of $13.55M over the trailing twelve months, while simultaneously recording a net income of $-25,315,000 and an EBITDA of $-25,141,000. The substantial gap between the positive revenue figure and the significant net loss reveals a cost structure where expenses, likely driven by research, development, and regulatory compliance for the gastrointestinal imaging devices, vastly outpace the income generated from current sales. Free cash flow stands at $-13,007,125, which indicates that the company is currently consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity. Despite the negative cash flow, the balance sheet holds $10.11M in cash against only $887,000 in debt, creating a net cash position that provides a buffer against operational burn. The debt-to-equity ratio of 6.69 suggests a leveraged capital structure relative to equity, yet the low absolute debt level mitigates immediate solvency risks. Operating liquidity is supported by a current ratio of 3.77, which signifies that the company holds more than three times the current assets necessary to cover its short-term liabilities, indicating a conservative approach to working capital management. Return on Equity is recorded at -184.9% and Return on Assets at -90.6%, metrics that reveal that management is currently utilizing the company's equity and asset base to generate losses rather than returns, a typical characteristic of early-stage medical device firms awaiting product commercialization milestones.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A, reflecting the fact that the company does not currently generate positive earnings, which makes traditional earnings-based valuation multiples inapplicable. In the absence of a positive P/E, the Price to Book ratio of 22.08 serves as a primary valuation metric, indicating that the market values the company at more than twenty-two times its book value, which suggests a high premium attached to the company's intangible assets and future growth potential. The Price to Sales ratio is 22.98, while the EV/EBITDA stands at -12.02; these alternative metrics suggest that the market is pricing CapsoVision based on revenue generation and asset base rather than profitability, implying that investors are betting on a future turnaround or significant revenue expansion to justify the current valuation. The stock has traded within a 52-week range with a high of $15.37 and a low of $3.43, meaning the current market price fluctuates within this wide band, though the specific current price point is not provided in the available facts to calculate an exact percentage deviation from the high or low. The Beta value is listed as N/A, which precludes a direct comparison of the stock's price volatility relative to the broader market, suggesting that either the data is insufficient to calculate a standard beta or the stock's volatility profile is not standardized against the benchmark in the available dataset.
Growth & Income
Revenue growth year-over-year is recorded at 13.5%, whereas earnings growth is N/A due to the company's continued net losses, indicating that top-line sales are expanding while the bottom line remains negative. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm retains all of its earnings to reinvest into research, development, and the commercialization of its endoscopic imaging technologies rather than distributing cash to shareholders. The absence of a dividend payout ratio eliminates concerns about sustainability of payouts, as the company's strategy focuses entirely on funding its growth trajectory through retained earnings and existing cash reserves. Overall, the growth and income profile of CapsoVision, Inc. is characterized by positive revenue expansion coupled with significant operating losses and no income distribution, typical of a growth-stage medical device company prioritizing market penetration and product refinement over immediate profitability or shareholder returns.